Brief: Hyloris Acquires Patented Technology For Acute Coronary Syndrome In The U.S.

Hyloris Pharmaceuticals SA

13/10/2021 06:16

Oct 13 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS ACQUIRES BREAKTHROUGH, PATENTED TECHNOLOGY TO
DEVELOP
AND MARKET ASPIRIN IV IN THE U.S. IN ACUTE CORONARY SYNDROME
    * INITIALLY TARGETING A TOTAL ADDRESSABLE PATIENT POPULATION
OF
ABOUT 2 MILLION IN U.S.
    * ENABLES ACCELERATED DEVELOPMENT OF HY-073 (IV
ACETYLSALICYLIC
ACID), BRINGING ANTICIPATED FDA SUBMISSION DATE FORWARD TO END
2023
    * ENTERED INTO AN EXCLUSIVE, WORLDWIDE LICENSING AGREEMENT
WITH
RHOSHAN PHARMACEUTICALS INC. ("RHOSHAN")
    * AGREEMENT TO DEVELOP, MANUFACTURE, COMMERCIALISE
INTRAVENOUS
ACETYLSALICYLIC ACID FOR TREATMENT OF PATIENTS WITH SUSPECTED
ACS
    * WILL BE RESPONSIBLE FOR MANUFACTURING, COMMERCIALISATION
OF
PRODUCT; RHOSHAN WILL CONTINUE PRODUCT DEVELOPMENT, REGULATORY
AFFAIRS ACTIVITIES
    * RHOSHAN WILL RECEIVE AN UPFRONT PAYMENT OF $750,000
    * RHOSHAN IS ELIGIBLE TO RECEIVE $1.25 MILLION DEVELOPMENT
AND
REGULATORY MILESTONES
    * RHOSHAN IS ENTITLED COMMERCIAL-BASED MILESTONES, AS WELL
AS A
SHARE OF NET PROFIT
    * HYLORIS WILL PROVIDE MAXIMUM $7.5 MILLION IN RESEARCH AND
DEVELOPMENT FUNDING UP TO, AND INCLUDING, REGULATORY APPROVAL

Source text for Eikon:  ID:nGNEbjWqNV 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))